Document 1079
 DOCN  M9591079
 TI    (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent
       inhibitor of feline immunodeficiency virus infection.
 DT    9509
 AU    Vahlenkamp TW; De Ronde A; Balzarini J; Naesens L; De Clercq E; van Eijk
       MJ; Horzinek MC; Egberink HF; Department of Infectious Diseases and
       Immunology, Faculty of; Veterinary Medicine, Utrecht University, The
       Netherlands.
 SO    Antimicrob Agents Chemother. 1995 Mar;39(3):746-9. Unique Identifier :
       AIDSLINE MED/95314214
 AB    The antiviral efficacy of acyclic nucleoside phosphonates, including
       9-(2-phosphonylmethoxyethyl)adenine (PMEA) and
       (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine [(R)-PMPDAP] against
       feline immunodeficiency virus (FIV) infection was determined. (R)-PMPDAP
       showed the highest selectivity index (> 2,000) in vitro. Treatment of
       experimentally FIV-infected asymptomatic cats with PMEA or (R)-PMPDAP
       had no effect on the CD4+/CD8+ ratio. However, mean plasma viral RNA
       concentrations decreased significantly in the (R)-PMPDAP-treated cats.
       Our data show that, in comparison to PMEA, (R)-PMPDAP is a more potent
       and less toxic inhibitor of FIV replication both in vitro and in vivo.
 DE    Adenine/*ANALOGS & DERIVATIVES/PHARMACOKINETICS/THERAPEUTIC USE  Animal
       Antiviral Agents/PHARMACOKINETICS/*THERAPEUTIC USE  Cats  Feline
       Acquired Immunodeficiency Syndrome/*DRUG THERAPY/  METABOLISM
       *Immunodeficiency Virus, Feline  In Vitro  Organophosphorus
       Compounds/PHARMACOKINETICS/*THERAPEUTIC USE  RNA, Viral/BIOSYNTHESIS
       Support, Non-U.S. Gov't  T-Lymphocytes/VIROLOGY  Virus Replication/DRUG
       EFFECTS  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).